Celgene Corp (CELG) said on Wednesday it authorized the additional repurchase of up to $2.5 billion in common stock, effective immediately. In April, the biotechnology company said it repurchased about 2.35 million shares during the first quarter of 2012 for about $169 million. As of March 31, it had $1.218 billion remaining under its existing stock repurchase program.
